Results 191 to 200 of about 3,235 (226)
Some of the next articles are maybe not open access.
Real-life preliminary evidence for basophils as predictors of Tezepelumab response in severe asthma
Expert Review of Clinical ImmunologyBackground Severe asthma is a complex disease with persistent symptoms despite high-dose inhaled therapy. Tezepelumab, a monoclonal antibody targeting thymic stromal lymphopoietin (TSLP), has shown efficacy across asthma phenotypes.
V. Quaranta +8 more
semanticscholar +1 more source
Journal of Asthma
Severe asthma is a heterogeneous disease involving multiple inflammatory pathways, with significant therapeutic challenges. Biologic therapies targeting T2 inflammation improve outcomes but may, in rare cases, trigger hypersensitivity reactions due to ...
Maria Braganca +4 more
semanticscholar +1 more source
Severe asthma is a heterogeneous disease involving multiple inflammatory pathways, with significant therapeutic challenges. Biologic therapies targeting T2 inflammation improve outcomes but may, in rare cases, trigger hypersensitivity reactions due to ...
Maria Braganca +4 more
semanticscholar +1 more source
Tezepelumab: A Potential New Biological Therapy for Severe Refractory Asthma
International Journal of Molecular Sciences, 2021Alessandro Vatrella +2 more
exaly
Is tezepelumab the ubiquitous biologic for severe asthma?
The Lancet Respiratory Medicine, 2023Beasley, Richard, Chang, Anne B.
openaire +4 more sources
Efficacy of Tezepelumab in Patients with Severe, Uncontrolled Asthma and Perennial Allergy
Journal of Allergy and Clinical Immunology: in Practice, 2021Jonathan Corren +2 more
exaly
Allergic bronchopulmonary aspergillosis successfully treated with tezepelumab
The Journal of Allergy and Clinical Immunology: In Practice, 2023openaire +2 more sources
Tezepelumab in the Treatment of Uncontrolled Severe Asthma
Annals of Pharmacotherapy, 2023Pramodini Kale-Pradhan, Melissa Lipari
exaly